Updates in the Management of Myelodysplastic Syndromes (MDS)

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.

Expert panelists explore challenges impacting care access for patients with MDS.

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.

Experts discuss the impact of supportive care in the MDS treatment landscape.

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.

The expert panel looks to future treatment management for patients with myelodysplastic syndrome.

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.